Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

NCT02329860 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Apatinib
DRUG: Placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Collaborators

[object Object]